Also known as WT1. Protein that in most AML cells and also in a variety of solid tumors is expressed at levels high above normal expression levels. This overexpression makes WT1 an attractive tumor target. NTLA-5001 utilizes a TCR-directed approach to target the WT1 intracellular antigen for the treatment of AML.